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Summary 
The characterization of normal stem cells and cancer stem cells uses the same paradigm. 
These cells are isolated by a Fluorescent-Activated Cell Sorting step and their stemness is 
assayed following implantation into animals. However, differences exist between these two 
kinds of stem cells. Therefore, the translation of the experimental procedures used for normal 
stem cell isolation into the cancer stem cell research field is a potential source of artefacts. In 
addition, normal stem cell therapy has for objective the regeneration of a tissue, while cancer 
stem cell-centred therapy seeks the destruction of the cancer tissue. Taking these differences 
into account is critical for anticipating problems that might arise in cancer stem cell-centred 
therapy and for upgrading the cancer stem cell paradigm accordingly.  
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The cancer stem cell model. 
Accumulating evidence indicates that tumours are organized in a hierarchical pattern like 
normal tissues, with a small population of stem cells named “cancer stem cells” responsible 
for both development and maintenance of cancer tissue, and a majority of cancer cells with 
limited proliferative potential which form the bulk of the tumor (for reviews see references
(1-
3)
. In the cancer stem cell experimental paradigm, cancer stem cells are individually defined 
by their ability to serially regenerate tumours following implantation in animals. This property 
illustrates their unlimited proliferation potential, their ability to self-renewed and their 
capacity to generate a progeny of differentiated cancer cells with limited proliferative 
potential. Cancer stem cells share several distinctive properties with normal stem cell i.e. self-
renewal and extensive proliferation potentials, and capability to differentiate. However, the 
term cancer stem cell is not synonymous with “transformed stem cell”, since in many cases 
the nature of the cell to first acquire fully malignant properties, i.e. stem cell, progenitor or 
differentiated cell, remains unknown
(1). In other words, the term “cancer stem cell” defines a 
function, and does not refer to the identity of the initial transformed cell that originated the 
tumor.  
The concept of cancer stem cell is of paramount importance. If cancer stem cells represent the 
only cell population with tumorigenic potential, then one would hypothesize that these cells 
are not only involved in the maintenance of the primary tumour mass but may also play a 
critical role in metastasis and relapse
(4-7)
. Regarding metastasis, although the cancer stem cell 
phenotype is not always sufficient to establish metastases, a subpopulation of migrating 
cancer stem cells involved in tumour metastasis has already been detected in human breast 
and pancreatic cancers
(4,5)
. Concerning relapse, the mechanisms involved in the therapeutic 
resistance of cancer stem cells include for example the preferential activation of the DNA 
damage checkpoint response, and increased Wnt/β-catenin and Notch signalling(8). Drug 
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pumps are also preferentially expressed in cancer stem cells
(9)
. Notably, one of these drug 
transporters involved in chemoresistance, named ABCG2, is the determinant of the Side 
Population phenotype (SP) which is used for characterizing some normal and cancer stem 
cells
(10,11)
. Hence, in the cancer stem cell model, a therapy targeting cancer cells but sparing 
the cancer stem cell population will induce only temporary regression. Therefore, the isolation 
and the characterization of cancer stem cell are of crucial concern for both basic cancer 
research and for designing novel efficient therapies.  
The purpose of this paper is to discuss the weaknesses of the assays currently used to isolate 
and characterize the different subpopulations of cancer stem cells that are important for 
tumour growth and are not efficiently targeted by current therapies. We show that applying 
the same experimental paradigms for the isolation of normal and cancer stem cell can be 
misleading because these two kinds of stem cells have fundamental distinct features. 
Moreover, the goals of cancer stem cell-centred therapy and regenerative therapy are 
opposite. Cancer stem cell therapy seeks to eliminate a tissue whereas regenerative stem cell 
therapy looks for tissue growth. Taking into account these fundamental differences is critical 
for the future of cancer stem cell research. 
 
Flow cytometry: the gold standard for stem cell isolation. 
Since the introduction of monoclonal antibodies directed against cell surface antigens, flow 
cytometry is the method of choice for characterizing and sorting normal stem cells. Currently, 
the multi-parameter analysis based on cell surface antigens expression or on the capability to 
efflux fluorescent dyes, allows one to assess the phenotype of cells residing at the top of the 
differentiation pyramid of the haematopoietic system. The conceptual analogy between the 
hierarchical organization of normal and cancer tissues coincides with experimental analogies 
in the methods used to isolate normal and cancer stem cells. This similarity is evident when 
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the experimental methods developed for assaying either haematopoietic or cancer stem cell 
potentials are compared (Fig 1).  
Basically, the isolation of normal or cancer stem cells requires a cell sorting step that 
is followed by an in vivo repopulation/tumorigenicity assay, in which the potential of sorted 
cells to reconstitute normal or tumoral tissues after implantation in animals is evaluated (Fig. 
1). This cell sorting step is based on the detection of cell surface antigens or on the ability of 
some stem cells to efflux the vital fluorescent dye Hoechst 33342. For example, 
haematopoietic stem cells (HSC) were first characterized from bone marrow as CD34
+(12,13)
. 
Currently, other cell surface markers such as the CD133 epitope recognized by the mAb 
AC133 are used to identify human HSC and some cancer stem cells
(14,15)
. On the other hand, a 
functional assay based on the ability of stem cell to extrude the fluorescent Hoechst 33342 
dye (side-population or SP assay) is also widely used to isolate HSC
(10)
 or cancer stem 
cells
(11,16,17)
.  
Thus, normal or cancer stem cells characterization requires a Fluorescence Activated 
Cell Sorter (FACS) analysis step, since even when magnetic-activated cell sorting (MACS) is 
used, the purity of the sorted cell population needs to be evaluated by FACS. However, even 
though immunophenotyping and SP assays are the gold standards for identifying normal or 
cancer stem cells, these two methods are basically different.  SP analysis is a functional assay 
evaluating the capability of cells to extrude a fluorescent dye, while immunophenotyping is a 
structural assay which detects the expression of cell surface markers. 
 5 
 
Fig. 1 
Normal stem cell and cancer stem cell assays. 
The experimental steps used to characterize cancer stem cells follow the experimental 
paradigm of normal stem cell characterization. At first, cells are isolated from tissue 
and then sorted by FACS either on their capacity to efflux Hoechst 33342 (SP 
phenotype) (A,B), or on the basis of the expression of CD34 for haematopoietic stem 
cells and CD133 for brain cancer stem cells (immunophenotyping) (C,D). In a 
haematopoietic stem cell assay (A,C), normal stem cells prospectively isolated by 
FACS, are assayed for their capability to rescue lethally irradiated mice from 
radiation-induced bone marrow aplasia, and for their ability to provide permanent 
long-term engraftment
(83)
. In a cancer stem cell assay (B,D), cancer stem cells 
prospectively isolated by FACS are implanted into an orthotopic site of 
immunocompromised mice and are assayed for their capability to serially induce 
tumor formation.  
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Sorting cancer stem cells on the basis of a functional test: The SP phenotype 
  
History. 
 Hoechst 33342 is a fluorescent dye designed by the Hoechst firm in 1974 with the aim of 
providing new chemotherapeutic agents
(18)
. This drug is part of a family of fluorescent vital 
dyes and has an excitation wavelength at around 350 nm. Hoechst 33342 binds to DNA and 
has been first used to visualize nuclei, to quantify cell DNA content, and for sorting living 
cells according to the different phases of the cell cycle
(19)
. Interestingly, this compound emits 
at two wavelengths of fluorescence, blue and red, when it binds to DNA. This polychromatic 
fluorescence emission depends on the intracellular concentration of the dye
(20)
 and is critical 
for characterizing the SP phenotype. In 1996 Goodell, demonstrated that mice HSC have the 
distinct feature to efflux this dye
(10)
; this property is the basis of the SP assay which has been 
used since in more than one hundred studies to characterize normal or cancer stem cells.  
 
Functional basis. 
The property of some stem cells to efflux Hoechst 33342 defines by FACS analysis a minor 
population of low labelled cells referred to as “SP” cells(10,11). These low-labelled cells are 
detected as a distinct population in the left lower quadrant of FACS profiles (Fig 1B and 2A).  
Bcrp1/ABCG2 expression has been shown to be the determinant of the SP phenotype in bone 
marrow cells
(21-23)
. However, depending on the tissue, other ABC transporters can contribute 
to the SP phenotype. For example, both Bcrp1/ABCG2 and Mdr1a/b (Abcb1a/1b) play a part 
in the SP phenotype in the mammary gland
(24)
. Since a drug transporter such as ABCG2 is the 
functional basis of Hoechst outflow, a control experiment with verapamil an ABCG2 pump 
inhibitor, must be included for each experiment. In these control experiments, the presence of 
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verapamil during the assay leads to the disappearance of SP cell population (Fig. 1B and 2B). 
An important consequence of the involvement of the Bcrp1/ABCG2 drug-transporter in the 
determination of the SP phenotype is that SP cells are de facto resistant to several drugs such 
as mitoxantrone, and methotrexate
(25)
. 
 
Controversies:  
Verapamil-sensitive upper SP cells:  
Although settings for SP analysis place the cell-sorting gate in the left lower quadrant, a more 
careful examination of FACS profiles obtained in the presence of verapamil demonstrates the 
existence of other SP cells located in the left upper quadrant of FACS profile
(26,27)
. This upper 
cell population is evident in cancer cell lines (Fig. 2C). In several cancer stem cell 
experiments, the addition of verapamil induces a convex-concave transition of FACS profiles 
(see for example
(11,26)
). The fact that this observation is not readily observable with normal 
low cycling cells such as HSC suggests that this upper SP cell population could correspond to 
SP cycling cells or SP polyploid cells
(26,27)
. Unfortunately, this upper SP was not further 
characterized and goes unnoticed by most investigators working in field of cancer stem cells 
(11,26)
, illustrating our tendency to use the same experimental paradigm for studying normal 
and cancer stem cells regardless the fundamental differences existing between these two cell 
types.  
 
Hoechst 33342 activities: 
A recurrent question regarding the use of Hoechst 33342 in SP analysis is the consequence of 
Hoechst staining on cell viability and differentiation since Hoechst 33342 interacts with DNA. 
Indeed, the biological consequence of Hoechst nuclear staining is a particularly relevant point 
in cancer research where many DNA-labelling agents have important cancer therapeutic 
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effects. In fact, it has long been known that Hoechst 33342 can be cytotoxic depending on the 
concentration and the cell type used
(28,29)
. Moreover, it is noteworthy that Hoechst interferes 
with cancer cell differentiation at concentrations used for SP analysis
(30-32)
. Unfortunately, 
these data are largely ignored.  
Although the mechanism by which Hoechst 33342 influences cell differentiation has 
not been specifically addressed, several reports demonstrate that Hoechst 33342 poisoned 
topoisomerase I with a similar mechanism of action as camptothecin
(33)
. This point is of 
particular concern since topoisomerase I inhibitors are known to induce cancer cell 
differentiation
(34,35)
. Hence, an evaluation of Hoechst 33342 effects on cancer cell 
differentiation should be included in any SP analysis demonstrating a difference between SP 
and non-SP cells. Regrettably, these control experiments, which are much more cumbersome 
than evaluating Hoechst cytotoxicity, are never performed. The fact that Hoechst 33342 
disrupts TATA box-binding protein/DNA complexes
(36) 
also raises concerns on the 
transcriptomics data that compare SP and non-SP cells.  
Functional independence of normal stem cells for SP phenotype.  
 Bcrp1/ABCG2, the molecular determinant of the SP phenotype, is expressed in a wide 
variety of stem cells
(23)
. However, although a large reduction in the number of SP cells is 
detected in bcrp1 null mouse, the HSC compartment is not affected in these null mice
(22)
. 
Moreover, the SP phenotype could be dispensable for stem cell function since these mice 
show no obvious stem cell pathology. This could explain some conflicting results obtained 
with cancer stem cells when SP phenotype fluctuates independently of stemness
(26)
. An 
important point is that, concerning solid tumors, SP analyses are usually done on cancer cell 
lines or on primary cancer cells which have been amplified in culture. Therefore, the 
extrapolation of the data to the behaviour of the cells in vivo can be debatable. The situation is 
different for leukemic cells and for normal hematopoietic cells which are usually analysed 
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immediately after isolation
(10,37,38)
. Notwithstanding these limitations since Bcrp1/ABCG2, 
which is the functional determinant of the SP phenotype is an ABC transporter involved in 
drug resistance, the SP phenotype provides a selective advantage when cells are challenged 
with anticancer drugs such as the topoisomerase I inhibitor topotecan or the antifolate agent 
methotrexate
(39)
. Hence, the SP phenotype defines a population of chemo-resistant cancer 
cells, and this approach is pertinent from a therapeutic standpoint. The recent finding 
suggesting that therapeutic blockade of either PI3K or Akt might reduce ABCG2 function in 
cancer stem cell in vivo is, in this context, highly relevant
(40)
. 
  
 
Fig.2 
The upper SP: how the blind adherence to the academic SP cell gating procedures can 
hinder a relevant cancer SP cell population.  
In a typical SP analysis, cells are labelled with Hoechst 33342 in the presence or absence of 
an ABCG2 inhibitor such as verapamil. The SP cell population assimilated to cancer stem 
cells is defined as the population of cells that actively outflow Hoechst by a verapamil 
sensitive process. Therefore, in FACS profiles, the SP region which corresponds to low 
labelled cells, is indicated by a trapezoid on the left lower quadrant of FACS profile (A). In 
the presence of verapamil, cells which are localized in the SP region disappears (B). However, 
when SP analyses are performed on cancer cell lines, another verapamil sensitive population 
is readily detectable in the left upper quadrant of FACS profile (C,D). Unfortunately this cell 
population remains unnoticed in almost all published analyses. In the example shown, which 
is performed on C6 glioma cells, roughly half of the verapamil-sensitive cells are found in this 
upper side population. Although these cells have not been fully characterized they probably 
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correspond to cycling cells. Indeed this upper SP is not detectable when SP analysis is 
performed on low-cycling diploid cells such as bone marrow cells (A,B). This example 
illustrates the limitations of transferring a technology validated in normal stem cell studies to 
cancer stem cell studies without considering the special features of cancer cells.  
 
 
 
Sorting cancer stem cells on the basis of a structural test. Immunophenotyping cancer 
stem cells on the basis of cell surface markers. 
History. 
Cancer stem cells immunophenotyping originates directly from methods used more than 30 
years ago to identify the heterogeneous populations of cells within bone marrow
(12)
. 
Nowadays, prospective cancer stem cells are isolated by flow cytometry on the basis of cell 
surface markers expression, just like haematopoietic stem cells are
(41-46)
. For example, the 
cancer stem cell population has been defined as CD34
+
CD38
-
 in acute myeloid leukaemia 
(47) 
CD133
+
 in brain
(45)
, melanoma
(48)
 and lung tumors
(49)
, CD133+(43,44) or 
EpCAM
high
/CD44
+
/CD166
+
 in colon cancer
(42)
, CD44
+
/CD24
-/low
/Lineage
-
 in breast 
tumors
(41)
, CD44
+
/CD117
+
 in ovarian tumors
(46)
, and CD44
+
/21
hi
/CD133
+
 in prostate
(50)
. In 
all cases, the prospective cancer stem cell populations sorted on the basis of cell surface 
markers are then characterized by their ability to regrow a tumor in xenotransplantation 
assays. This xenograft assay can be viewed as the parallel of the repopulation assay used in 
haematopoietic stem cell research. Importantly none of the antigens used for identifying 
cancer stem cells is exclusively expressed on cancer cells since, for example CD34 and 
CD133 cell surface antigens are also used to immunophenotype normal stem and progenitor 
cells in several tissues
(51,52)
. 
 
Functional basis. 
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Contrary to the SP phenotype, which relies on the functionality of a drug transporter involved 
in multidrug resistance and therefore in cancer chemoresistance, the immunophenotyping 
assay can target membrane proteins not necessarily involved in the “cancer stem cell” 
function. For example, AC133 one of the most widely antigens used for cancer stem cell 
immunophenotyping corresponds to CD133, a protein whose function remains elusive. 
However, even if the role of CD133 in cancer is not elucidated, CD133
+
 cells have 
nevertheless been reported to have important features such as an increased 
radioresistance
(53,54) 
and increased expression of VEGF
(55)
. On the other hand, other antigens 
used for immunophenotyping are directly implicated in cancer process. For example, the cell 
surface marker EpCAM  is used for immunophenotyping and is known to up-regulate c-myc 
and cyclin A/E, and to induce cell proliferation
(56)
.  
 
Controversies. 
-Effect of cell sorter optical configuration, inter-laboratory variability, and the need 
for a standard of measurement. 
A large prpoportion of the cell sorters commercialised during the end of the 1990s and the 
beginning of the 2000s such as the FACS Vantage SE from BD Bioscience have an optical 
configuration that does not allow the optimal collection of the fluorescences emitted by 
stained cells
(57)
. These devices are still used nowadays in numerous flow cytometry core 
laboratories. Since the optics of the current machines such as the LSR II from BD Bioscience 
with a quartz device are more efficient at capturing the emitted light than the stream-in-air 
system of the old sorters, the percentages of positive cells acquired in these two cases widely 
differ. This point becomes critical when negative and positive cell populations form a 
continuum. In this regard it is noteworthy that FACS analyses cluster cells on the basis of 
positive, negative, low, or high fluorescent intensity. In a sense, FACS is a highly efficient 
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technology of measurement that has forgotten to define an objective standardised unit of 
measurement relevant to the parameter studied. The judicious selection of a standard for 
FACS analysis, which could for example consider the number of epitopes by cell, is therefore 
critical for ensuring the inter-laboratory reproducibility of experimental results
(58,59)
. 
 
-Immunophenotyping and SP analyses: similarity, overlap and discrepancy.  
The basic tenet of cancer stem cell research is that cancer stem cells represent a unique 
population of cancer cells responsible for tumour maintenance and recurrence. Hence, it is 
critical to characterise these cells as they are priority therapeutic targets.  In this context, it 
could have been expected that cancer stem cell populations characterized by 
immunophenotyping and SP analysis coincide, and that immunophenotyping using different 
cancer stem cell markers identifies, for a given neoplasm, a unique population of cancer stem 
cells. However, several studies report a limited overlap between cancer stem cell populations 
obtained using different cell sorting procedures. For example, in some glioma cell lines, 
CD133
+
 cells are not SP
(60)
. Likewise in DAOY medulloblastoma cells CD133 and SP subsets 
can be two independent compartments
(61)
.  
Although, these data have been obtained with cultured cell lines and might not be 
representative of the situation found in vivo, other results obtained by immunophenotyping 
human colorectal xenograft cells which have never been maintained in culture also show 
some inconsistencies. Thus, the expression of CD133, which has been described as a 
colorectal cancer stem cell marker
(43,44)
, is variable in the cancer stem cell population 
characterized on the basis of CD44 expression
(42)
 or in colon metastatic cancer stem cell
(51)
. 
Likewise, although brain cancer stem cells were first identified as CD133+
(45)
, several recent 
reports demonstrate the existence of CD133
-
 cancer stem cells in brain tumors
(62-65)
. Hence, 
the use of a single marker such as CD133 for immunophenotyping cancer stem cells could 
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underscore the heterogeneity of the cancer stem cell phenotype as well as the complexity of 
cancer disease. This emphasizes the importance of phenotyping cancer stem cells on the basis 
of cell surface marker repertoires. 
 
-Cancer stem cell marker constancy. 
Constancy of antigens expression is critical for the relevance of cancer stem cell 
immunophenotyping. However, as mentioned earlier, a potential drawback of 
immunophenotyping is that most of the antigens used do not seem to be directly involved in 
the maintenance of the cancer stem cell function. This situation contrasts with the principle of 
SP analysis which targets the functionality of ABCG2/Bcrp1, a protein involved in drug 
resistance
(25)
. Hence, inconsistencies may occur in the immunophenotyping of cancer stem 
cells if the markers used are not under selective pressure. Contrary to normal stem cells which 
have developed several genomic safeguard mechanisms and reside in a unique well-defined 
microenvironment (the stem cell niche), cancer stem cells are genetically and epigenetically 
unstable cells which are challenged by changing microenvironments not only in the primary 
tumor site, but also during metastatic process, and in cell culture. Hence, as cancer is an 
evolutionary system
(25,66,67)
, the stability of expression over time of a cancer stem cell-
associated antigen may depend on the role of this antigen in the maintenance of the cancer 
stem cell function. This could explain the inconsistency reported above in the use of CD133 
to characterise cancer stem cells in brain and colon cancers since the functional contribution 
of this antigen to cancer stem cell function remains obscure. Thus, both CD133
+
 and CD133
-
 
cells with cancer stem cell functions can appear in a tumour during tumour progression and 
metastasis.  
In this regard it is note-worthy that environmental conditions, such as low oxygen 
tension has been described to up regulate CD133 expression
(54,68,69)
. This finding suggests that 
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CD133
+
 cells might be cancer cells challenged to a hypoxic microenvironment. Hence the 
existence of multiple subsets of “cancer stem cells” with different antigenic profiles, even for 
tumours of a given tissue, must now be integrated into the cancer stem cell paradigm. The 
characterization of the functional role of the cell surface markers used in cancer stem cell 
immunophenotyping is therefore critical. In a sense, sorting cancer stem cells on the basis of a 
functional test such as the SP assay provides both information and understanding since 
Bcrp1/ABCG2 function is involved in the drug resistance of tumour stem cells. However, 
immunophenotyping cancer stem cells on the basis of epitopes whose function is not yet 
defined provides only information. 
 
FACS in normal stem cell and cancer stem cell medicine: One technical approach for 
two different therapeutic goals. 
FACS analysis of cell surface molecules, by its ability to isolate rare cell types to high purity, 
had a critical impact first on haematopoietic stem cell research, and then on leukaemia 
research and diagnosis
(70,71)
. However, transferring the concepts and methods developed in the 
context of HSC research to cancer stem cell entities in solid tumors requires a cautious 
consideration of the clinical difference existing between the therapeutic purpose of a 
regenerative therapy and that of a stemicide therapy. For example, regarding normal stem cell 
regenerative therapy, although LT-HSC have been first described as CD34
+
 or SP, very rare 
CD34
-
 and non-SP subsets of LT-HSCs also exist
(72,73)
. Therefore, sorting HSC on the basis of 
CD34 expression or SP phenotype eliminates a functionally minor but relevant stem cell 
population. Omitting these CD34
-
 or non-SP LT-HSC, however does not seem to have clinical 
consequences in the repopulation assay since successful haematopoietic reconstitution can be 
therapeutically achieved with either CD34
+
 or SP LT-HSC cells only. Therefore, in normal 
stem cell regenerative medicine, the therapeutic achievement can be obtained with only one 
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the stem cell subpopulation. Likewise, if the cancer stem cell function is supported in the 
patient by heterogeneous population of cancer stem cells, the implantation of only one of 
these cancer cell populations is sufficient to regrow the tumour. This outcome fulfils the 
experimental goal of the xenograft assay model, which is the regeneration of the tumour in the 
animal. However, in cancer medicine, the therapeutic goal is the eradication of the natural 
tumour, not its regeneration. If we consider that at the time of diagnosis or recurrence, the 
primitive cancer stem cell has generated several cancer stem cell sub-populations differing not 
only genetically or epigenetically, but also according to their surrounding microenvironment 
and metastatic potential, then a successful stemicide therapy requires the characterization and 
the targeting of all the cancer stem cell populations present in the patient.  
Unfortunately, in a xenograft assay, cancer cells implanted in mice are challenged to a 
microenvironment very different from the cancer mass from which they are issued. Hence, the 
xenograft assay may fail to detect human cancer stem cell populations unable to grow in 
immunocompromised animal but nevertheless capable of sustaining tumour growth in 
patient
(74,75)
. The fundamental difference existing between a regenerative and a stemicide stem 
cell therapy, and the low sensitivity of the xenograft assay, are two possible explanations for a 
potential disappointing outcome for cancer stem cell-centred therapies.  
 
Concluding remarks and perspectives. 
Cancer research is a relatively old field of investigation, and its experimental paradigms have 
successively evolved throughout the last century according to the most available frames of 
reference
(74)
. Recently, stem cell biology became a new frame of reference in medical 
research as evidenced by the increase in the number of journals covering this field (Stem 
Cells, first issue 1983; Stem Cell and Development, first issue 1999; Stem Cell Research, first 
issue 2007; Cell Stem Cell, first issue 2007). This could, in part, explain the recent revival of 
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the cancer stem cell concept whose origin is more than a century old
(76)
. As biology is an 
experimental science, emergence of new reference frames is often linked to the development 
of new experimental tools. For example, more than one century ago, the development by 
Koch and Petri of a solid media enabling the rapid isolation of pure cultures from 
contaminated specimens was a major breakthrough in the development of medical 
microbiology
(77,78)
. Interestingly, FACS now achieves the same goal as was achieved by solid 
media and the Petri dish, that is, cell cloning. However, we must be aware of the current 
limitations of the FACS experimental procedures used to isolate cancer stem cells (Table 1). 
The determination of the functional role played by the different cell surface antigens used for 
cancer stem cell immunophenotyping is critical. Cancer is in development at all times, and 
cancer cells are engaged in an evolutionary process which occurs in a very short period of 
time as limited to the timescale of the illness
(66,67)
. This ecological and evolutionary process 
involves genetically and epigenetically unstable cancer cells confronted with changing 
physiological and non-physiological microenvironments. In this context the expression of 
cancer stem cell epitopes not directly involved in critical stemness functions could fluctuate. 
Therefore, identifying cell surface antigens whose function is mandatory for cancer stemness 
is of paramount importance.  
In the absence of such key markers, FACS analyses need to evolve. More complex 
analyses, taking into account the intensity of cell labelling (high, medium, low, negative) and 
involving panels of antigens as recently done for colon and breast cancer stem cells
(41,42)
 are 
required. These analyses could target cell surface proteins involved in critical cancer stem cell 
functions such as chemokine receptors (CXCR4, CXCR3…)(79) adhesion proteins 
(L1CAM…)(7), or ABC drug transporters(25). Even if these proteins are also expressed on 
normal cells, a cancer stem cell specific pattern of expression can be expected to emerge. 
Functional in vitro assays evaluating for example, invasion and angiogenic assays in 
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Matrigel
(80,81)
 could also be included for characterizing cancer stem cell subpopulations. The 
evolution of cancer stem cell analyses toward a combination of such structural and functional 
multiparametric assays is necessary if we consider the complexity of the cancer stem cell 
phenotype. 
However, cancer stem cell characterization is not limited to a FACS sorting step. The 
stemness of cells prospectively isolated by FACS must be functionally assayed in xenograft 
experiments. In that case, the overall sensitivity of the cancer stem cell isolation procedure is 
limited by the experimental step with the lowest threshold of detection. One of the weak link 
of the cancer stem cell experimental paradigm resides in the sensitivity of the xenograft assay 
which needs to be improved as it can underestimate the frequency of cancer stem cells
(4)
. 
Notably, it has been recently shown that the use of more highly immunocompromised mice 
increases the detectable frequency of cancer stem cells
(4)
. Numerous studies have 
demonstrated that microenvironment can either support or inhibit tumorigenesis
(82,83)
. Cancer 
stem cell assays are presently performed by implanting cancer cells in normal orthotopic 
tissue. A tumourigenicity assay based on the injection of cancer cells in pre-tumoral niches 
could reveal the existence of new class of cancer stem cells not previously detected by the 
present classical assays.  
In conclusion, the parallel between normal and cancer stem cells is both conceptually and 
experimentally rewarding. However, the striking similarities between normal and cancer stem 
cells should not understate the fundamental differences existing between these cells (Table 1). 
Taking into account these distinctions is essential for upgrading the experimental paradigm 
currently used in cancer stem cell research and for the development of therapies which will be 
able to target cancer stem cells while sparing normal stem cells. 
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Legends to figures 
 
Fig. 1 
Normal stem cell and cancer stem cell assays. 
The experimental steps used to characterize cancer stem cells follow the experimental 
paradigm of normal stem cell characterization. At first, cells are isolated from tissue 
and then sorted by FACS either on their capacity to efflux Hoechst 33342 (SP 
phenotype) (A,B), or on the basis of the expression of CD34 for haematopoietic stem 
cells and CD133 for brain cancer stem cells (immunophenotyping) (C,D). In a 
haematopoietic stem cell assay (A,C), normal stem cells prospectively isolated by 
FACS, are assayed for their capability to rescue lethally irradiated mice from 
radiation-induced bone marrow aplasia, and for their ability to provide permanent 
long-term engraftment
(83)
. In a cancer stem cell assay (B,D), cancer stem cells 
prospectively isolated by FACS are implanted into an orthotopic site of 
immunocompromised mice and are assayed for their capability to serially induce 
tumor formation.  
 
Fig.2 
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The upper SP: how the blind adherence to the academic SP cell gating procedures can 
hinder a relevant cancer SP cell population.  
In a typical SP analysis, cells are labelled with Hoechst 33342 in the presence or absence of 
an ABCG2 inhibitor such as verapamil. The SP cell population assimilated to cancer stem 
cells is defined as the population of cells that actively outflow Hoechst by a verapamil 
sensitive process. Therefore, in FACS profiles, the SP region which corresponds to low 
labelled cells, is indicated by a trapezoid on the left lower quadrant of FACS profile (A). In 
the presence of verapamil, cells which are localized in the SP region disappears (B). However, 
when SP analyses are performed on cancer cell lines, another verapamil sensitive population 
is readily detectable in the left upper quadrant of FACS profile (C,D). Unfortunately this cell 
population remains unnoticed in almost all published analyses. In the example shown, which 
is performed on C6 glioma cells, roughly half of the verapamil-sensitive cells are found in this 
upper side population. Although these cells have not been fully characterized they probably 
correspond to cycling cells. Indeed this upper SP is not detectable when SP analysis is 
performed on low-cycling diploid cells such as bone marrow cells (A,B). This example 
illustrates the limitations of transferring a technology validated in normal stem cell studies to 
cancer stem cell studies without considering the special features of cancer cells.  
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